Asfotase alfa is a hydroxyapatite-targeted recombinant form of TNSALP indicated for use in life-threatening perinatal/infantile and severe childhood or juvenile-onset cases of HPP in the United States, Canada, Europe, and Japan [17]. The gene discussed is ALPL; the disease is hypophosphatasia.